Pacira BioSciences (PCRX) said Monday that two-year results from a Phase 1 study showed its gene therapy candidate PCRX-201 provided sustained improvements in pain, stiffness, and function in patients with knee osteoarthritis.
Patients who received corticosteroid pretreatment experienced greater reductions in pain and stiffness, the company said.
PCRX-201, which boosts production of an anti-inflammatory protein, was generally well tolerated, with mild to moderate joint swelling as the most common side effect.
Pacira is currently enrolling patients in a phase 2 study of PCRX-201 for knee osteoarthritis.
Shares of Pacira were up 2.7% in recent trading.
Price: 26.41, Change: +0.69, Percent Change: +2.68
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。